#Vaccine covid trial#
The trial showed a 94.1% reduction in the number of symptomatic COVID-19 cases in the people who received the vaccine (11 out of 14,134 vaccinated people got COVID-19 with symptoms) compared with people who received dummy injections (185 out of 14,073 people who received dummy injections got COVID-19 with symptoms). People did not know whether they received the vaccine or the dummy injections.Įfficacy was calculated in around 28,000 people from 18 to 94 years of age who had no sign of previous infection. Half received the vaccine and half were given dummy injections. The trial involved around 30,000 people in total. What benefits of Spikevax have been shown in studies?Ī very large clinical trial showed that Spikevax, given as a two-dose regimen, was effective at preventing COVID 19 in people from 18 years of age. The mRNA from the vaccine does not stay in the body but is broken down shortly after vaccination.
If, later on, the person comes into contact with SARS-CoV-2 virus, their immune system will recognise it and be ready to defend the body against it.
The person’s immune system will then recognise this protein as foreign and produce antibodies and activate T cells (white blood cells) to attack it. When a person is given the vaccine, some of their cells will read the mRNA instructions and temporarily produce the spike protein.
An adapted vaccine works in the same way as the original vaccine and is expected to broaden protection against the virus as it also contains mRNA matching other variants of the virus. This is a protein on the surface of the SARS-CoV-2 virus which the virus needs to enter the body’s cells and can differ slightly between variants of the virus. It contains a molecule called mRNA which has instructions for making the spike protein. Spikevax works by preparing the body to defend itself against COVID-19. The vaccine should be used according to official recommendations, issued at national level, by public health bodies.įor more information about using Spikevax and Spikevax bivalent Original/Omicron BA.1, see the package leaflet or consult a healthcare professional. A booster dose of Spikevax can also be given to adults at least 3 months after primary vaccination with another mRNA vaccine or an adenoviral vector vaccine.Ī booster dose of Spikevax bivalent Original/Omicron BA.1 may be given to adults and adolescents from the age of 12 years, at least 3 months after primary vaccination or a booster dose with a COVID-19 vaccine. Adults and adolescents from the age of 12 are given 100 micrograms per dose children aged 6 to 11 years are given 50 micrograms per dose.Īn additional dose of Spikevax may be given to people aged 6 years and older with a severely weakened immune system, at least 28 days after their second dose.Ī booster dose of Spikevax may be given at least 3 months after the second dose to adults and adolescents aged 12 years and older. Spikevax is given as two injections, usually into the muscle of the upper arm, 28 days apart.
0 kommentar(er)
